An MRI of a brain tumor
inviCRO has raised $45.8 million in its first disclosed financing. The money will be used to offer imaging services and analysis to aid drug research and development, according to a regulatory filing.
This news comes just after the Boston-based startup acquired Molecular Neuroimaging (MNI), expanding its neurological imaging options.
BioLabs Pegasus Park Cultivates Life Science Ecosystem
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
As Fierce Medical Devices reported, inviCRO helped open the Translational Imaging Center in Mattawan, MI that it co-manages with MNI Research and 3D Imaging; inviCRO provides molecular imaging, while 3D imaging offers radiopharmaceutical services and MNI contributes its CRO services.
The company is continuing to expand, considering last year it also acquired a Seattle-based histology team.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
